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The severe acute respiratory syndrome coronavirus (SARS-CoV), isolated from humans infected during the peak of epidemic, encodes two
accessory proteins termed as 8a and 8b. Interestingly, the SARS-CoV isolated from animals contains an extra 29-nucleotide in this region such that
these proteins are fused to become a single protein, 8ab. Here, we compared the cellular properties of the 8a, 8b and 8ab proteins by examining
their cellular localizations and their abilities to interact with other SARS-CoV proteins. These results may suggest that the conformations of 8a and
8b are different from 8ab although nearly all the amino acids in 8a and 8b are found in 8ab. In addition, the expression of the structural protein,
envelope (E), was down-regulated by 8b but not 8a or 8ab. Consequently, E was not detectable in SARS-CoV-infected cells that were expressing
high levels of 8b. These findings suggest that 8b may modulate viral replication and/or pathogenesis.
© 2006 Elsevier Inc. All rights reserved.Keywords: Severe acute respiratory syndrome (SARS); Coronavirus (CoV); Accessory proteins; Envelope (E) protein; 8a; 8b; 8abIntroduction
A novel coronavirus was identified as the aetiological agent
for the recent severe acute respiratory syndrome (SARS)
epidemic (Drosten et al., 2003; Poon et al., 2004). In addition
to the replicase polyproteins (pp1a and pp1ab) and structural
proteins (spike (S), membrane (M), nucleocapsid (N) and
envelope (E)), which are common to all members of the genus
coronavirus, the SARS-CoV genome also encodes eight
putative proteins with no significant sequence homology to
viral proteins of other known coronaviruses (i.e., open reading
frames (ORFs) 3a, 3b, 6, 7a, 7b, 8a, 8b and 9b) (Marra et al.,
2003; Snijder et al., 2003; Tan et al., 2005). Although it was
recently demonstrated that most of these so-called accessory
proteins are not essential for viral replication in cell culture or in
the murine model (Yount et al., 2005), the exact contributions of⁎ Corresponding author. Fax: +65 67791117.
E-mail address: mcbtanyj@imcb.a-star.edu.sg (Y.-J. Tan).
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doi:10.1016/j.virol.2006.06.026these proteins to viral replication or pathogenesis in the natural
host have not been established.
Interestingly, epidemiological studies have revealed that the
part of the viral genome that encodes for two of these
accessory proteins, 8a and 8b, shows major variations. In one
of these studies, Guan and co-workers (2003) analyzed SARS-
CoV isolates obtained from animals in a live-market in
Guangdong and found that all the animal isolates contain a
29-nucleotides (nt) sequence, which is absent in most of the
human isolates (Fig. 1A). As a result of this, the ORF8a and
ORF8b (also termed as ORF10 and ORF11, respectively) in
the human isolates become one ORF, termed as ORF8ab.
ORF8ab encodes a protein of 122 amino acids (aa), whose N
terminus is identical to 8a and C terminus is identical to 8b
(Fig. 1B). Another extensive study of 63 SARS-CoV isolates
obtained from the SARS epidemic in China also showed that
there are major variations in this region of the viral genome
(The Chinese SARS Molecular Epidemiology Consortium,
2004). In this study, the course of the epidemic was divided
into the early, middle and late phase with the early phase
Fig. 1. Expressions of SARS-CoV 8a, 8b and 8ab proteins. (A) Schematic diagram showing the genetic differences in the ORF8 region of the SARS-CoV isolated from
animals and humans infected during the middle phase of the SARS epidemic in 2003 (modified from Guan et al., 2003). The animal isolates have an extra 29-
nucleotides insertion such that the subgenomic RNA encodes for a single protein, termed 8ab, whereas that of the human isolates (from the middle phase) encodes two
proteins, 8a and 8b. Human isolates from early and late phases of the epidemic also have the 29-nucleotides insertion found in the animal SARS-CoV. (B) Alignment of
the sequences of 8a, 8b and 8ab proteins used in this study. Mismatches between 8a and 8ab or 8b and 8ab are boxed. The 8ab is reconstructed from a human isolate
from the middle phase (SIN2774) by insertion of the 29-nucletoides found in a human isolate from the early phase (GZ02). (C) Western blot analysis was performed to
detect 8a, 8b and 8ab proteins expressed in Vero E6 cells using cDNA constructs. The experiments were performed with either mouse anti-8a polyclonal antibody
(upper panel, lanes 1–4) or mouse anti-8b polyclonal antibody (upper panel, lanes 5–8). Equal amounts of cells were used in each lane as verified by the level of
endogenous actin (bottom panel).
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Guangdong Province. The middle phase referred to all events
up to the first cluster of SARS cases in the Metropole hotel in
Hong Kong and the late phase referred to all cases following
this cluster. Interestingly, the clustering of patients with
different patterns of variations in ORF8 region was correlated
with the different phases of the epidemic. These findings were
subsequently verified by researchers who studied the SARS-CoV isolated in different countries (Chiu et al., 2005; Lan
et al., 2005; Qin et al., 2003; Wang et al., 2004, 2005).
Although these mutations in the ORF8 region do not appear to
have any adverse effect on the survival of the virus, it is
conceivable that the 8a, 8b and 8ab proteins may have different
stabilities and/or functions and hence would contribute differently
to viral replication and/or pathogenesis in vivo. In order to
understand how the changes in the ORF8 region of the viral
Fig. 2. Cellular localizations of 8a and 8b in SARS-CoV-infected cells and Vero
E6 cells transfected with DNA constructs for expressing 8a, 8b and 8ab. Specific
mouse anti-8a and anti-8b polyclonal antibodies were used in indirect
immunofluorescence experiments to determine the expressions of (A) 8a and
(B) 8b, respectively. The top two panels showed the specific reactivities of the
anti-8a and anti-8b antibodies to proteins expressed in SARS-CoV-infected cells
(right panels) as no unspecific staining was observed for the mock-infected cells
(left panels). The bottom two panels showed the reactivities of the antibodies to
8a and 8ab (A) or 8b and 8ab (B) expressed in Vero E6 by transfection of cDNA
constructs.
Table 1
The interactions between SARS-CoV 8a, 8b and 8ab with other viral proteins
were determined by co-immunoprecipitation experiments
Bait
proteins a
Interacting partners b
S E M N 3a 7a
8a-myc Strong Weak No No No No
8b-myc No Strong Strong No Strong Strong
8ab-myc Strong No Weak No Strong Strong
a These proteins were immunoprecipitated using myc-polyclonal antibody
and protein A-agarose.
b These proteins were co-expressed with the bait proteins and co-
immunoprecipitation experiments were performed to be determined if they
could bind the bait proteins. The strengths of the binding were classified as
strong, weak or no interaction.
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compared the cellular properties of the human SARS-CoV 8a and
8b proteins with their counterpart, 8ab, in animal SARS-CoV.
Specific antibodies were produced and used to determine the
expression of 8a and 8b in SARS-CoV-infected cells. Indirect
immunofluorescence and co-immunoprecipitation experiments
were performed to compare the cellular localization of the 8a, 8b
and 8ab proteins and their abilities to interact with other SARS-CoV proteins. Finally, the specific effects of the 8b protein on the
expression of the small structural protein E in cells co-expressing
8b and E, and in SARS-CoV-infected cells were demonstrated.
Results
Polyclonal antibodies to the SARS-CoV unique proteins,
8a and 8b
For SARS-CoV isolated from humans infected in the middle
phase of the epidemic, the subgenomic RNA 8 encodes two
proteins, 8a and 8b, of 39 and 84 aa, respectively (Figs. 1A and
B). Mouse polyclonal antibodies were raised against bacterially
expressed GST-fusion 8a and 8b proteins. To determine the
specificity of these antibodies, Western blot analysis was
performed to detect 8a, 8b and 8ab expressed in transiently
transfected Vero E6 cells. As shown in Fig. 1C, mouse anti-8a
polyclonal antibody specifically detected 8a and 8ab whereas
mouse anti-8b polyclonal antibody detected 8b and 8ab. 8a and
8b migrated close to their predicted molecular weight of 4.5 kDa
and 9.6 kDa, respectively, whereas two forms of 8ab, ∼14 kDa
(major) and ∼12 kDa (minor), were detected (Fig. 1C). As the
predicted molecular weight of 8ab is 13.8 kDa, the minor form is
likely to have arisen from cleavage of the full-length protein.
Expression of 8a and 8b in SARS-CoV-infected Vero E6 cells
SARS-CoV 2003VA2774, an isolate from a SARS patient in
Singapore, was used to infect Vero E6 cells as previously
described (Tan et al., 2004b) and anti-8a or anti-8b polyclonal
antibodies were used in indirect immunofluorescence experi-
ments to determine the expression of 8a and 8b, respectively, in
infected cells (Figs. 2A and B). The 8a and 8b proteins were
detected in SARS-CoV-infected cells and were found to be
localized in the cytoplasm.
The same antibodies were used to examine the detailed
cellular localization of 8a, 8b and 8ab, expressed from DNA
constructs, in Vero E6 cells (Figs. 2A and B). Whereas 8a and 8b
were found in punctuate vesicle-like structures throughout the
cytoplasm, 8abwas found to be diffused in the cytoplasm. Hence,
there appears to be significant differences in the conformations of
8a and 8ab although 35 out of 39 aa of 8a is present in the 8ab
135C.-T. Keng et al. / Virology 354 (2006) 132–142protein (Fig. 1B). Similarly, 77 out of 84 aa of 8b is present in 8ab,
but the cellular localization of 8b is distinct from 8ab.
Interaction of 8a, 8b and 8ab with other SARS-CoV proteins
In order to further characterize the cellular properties of 8a,
8b and 8ab, co-immunoprecipitation experiments were per-
formed to determine if these proteins can interact with the
SARS-CoV structural proteins, S, M, E and N, as well as two
SARS-CoV accessory proteins, 3a and 7a, which were
previously shown to be expressed in SARS-CoV-infected
cells (Fielding et al., 2004; Tan et al., 2004b). All these proteins
were not tagged except for M, where the C terminus was fused
with a HA tag because of the lack of a suitable antibody for the
detection of M. 8a, 8b and 8ab were fused at their C termini withFig. 3. Interactions of 8a, 8b and 8ab with other SARS-CoV proteins. Cell lysates con
and another SARS-CoV protein (S, E, M-HA, N, 3a or 7a) were immunoprecipitate
amounts of S protein co-immunoprecipitated (IP) by the myc-tagged proteins were de
myc-tag proteins in the lysates before co-immunoprecipitation were also determi
respectively (middle and bottom panels). The same experiments were performed for p
used, namely (B) anti-E mouse polyclonal; (C) anti-HAmonoclonal (as the M protein
mouse polyclonal; (F) anti-7a mouse polyclonal.a myc tag so that it is possible to compare the relative expression
of the three proteins in this experiment. N-terminal-tagged myc-
GSTwas used as a negative control. The results showed that 8a-
myc interacted strongly with S, 8b-myc interacted strongly with
M, E, 3a and 7a and 8ab-myc interacted strongly with S, 3a and
7a (Table 1 and Fig. 3). These results showed that the binding
profiles of 8a, 8b and 8ab are clearly distinct, suggesting that the
conformations of the 8a and 8b proteins may be quite different
from the 8ab protein.
Overexpression of 8b down-regulates the expression of
E protein
While performing the co-immunoprecipitation experiments,
we observed that the expression of E was significantly reducedtaining myc-GST (lane 1), 8a-myc (lane 2), 8b-myc (lane 3) or 8ab-myc (lane 4)
d with an anti-myc polyclonal antibody and protein A-agarose beads. (A) The
termined using an anti-S monoclonal antibody (top panel). The amounts of S and
ned by Western blot (WB) with anti-S and anti-myc monoclonal antibodies,
anels B–F except that different antibodies against the specific viral proteins were
fused with a HA tag at the C terminus); (D) anti-N mouse polyclonal; (E) anti-3a
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8b-myc into 293 T cells were repeated using different amount of
the pXJ-8b-myc construct. As shown in Fig. 4A, the down-
regulation of E expression was specific and dependent on the
expression levels of 8b-myc (lane 3 and lanes 5–10). On the
contrary, the expressions of E were similar when pXJ-E was co-
transfected with control plasmid (pXJ-myc-GST) (lane 1) or
pXJ-8a-myc (lane 2) or pXJ-8ab-myc (lane 4).
In order to determine if 8b has any effect on the expression
of other SARS-CoV proteins, 8b was co-expressed with S
(Fig. 4B, lane 1) or M-HA (Fig. 4B, lane 3) or N (Fig. 4B,
lane 5) or 3a (Fig. 4B, lane 7) or 7a (Fig. 4B, lane 9). The
results showed that 8b did not have any significant effect on
the expression of these other viral proteins examined here.
The down-regulation of E expression by 8b was also ob-
served when untagged forms of 8b and E were co-expressed
in Vero E6 and 293 T cells (Fig. 4C, lanes 1 and 3). IndirectFig. 4. Effects of 8b on the expression of the small structural protein, E. (A) 293T cel
1 μg of pXJ-8a-myc (lane 2), pXJ-8b-myc (lane 3), pXJ-8ab-myc (lane 4), or decre
Western blot analysis to determine the expression of E (middle panel) and myc-tagged
the level of endogenous actin (bottom panel). (B) 293T cells were co-transfected with
Total cell lysates were subjected to Western blot analysis to determine the expression
each lane as verified by the level of endogenous actin (middle panel). Similar experim
(lanes 5 and 6), 0.4 μg of pXJ-3a (lanes 7 and 8) or 0.4 μg of pXJ-7a (lanes 9 and 10
pXJ-8b (lanes 1 and 3) or 1 μg of empty vector (lanes 2 and 4). Total cell lysates wer
and 8b (middle panel). Equal amounts of cells were used in each lane as verified by
experiments were performed to determine the cellular localization of 8b and E in
represented by FITC staining (left panel), whereas the expression of E is represented b
E partially colocalized in co-transfected cells (right panel).immunofluorescence experiments also showed that E and 8b
colocalized partially in Vero E6 cells (Fig. 4D).
Expression of 8b did not reduce the transcription of the E gene
In order to determine if the effect of 8b on the expression
of E is due to inhibition of the transcription of the E gene,
Northern blot analysis was performed to determine the
mRNA level of E in the presence or absence of 8b protein.
The results showed that the mRNA level of E was not
decreased in 293 T cells co-transfected with pXJ-E and pXJ-
8b-myc (Fig. 5, lane 2) when compared to cells transfected
with pXJ-E alone (Fig. 5, lane 1), but rather there appeared to
be an increase in the mRNA level of E in the presence of 8b.
This implies that the down-regulation of E protein expression
by 8b is not due to a reduction of the transcription of the E
gene and is likely to be post-translational. No signal wasls were co-transfected with 2 μg of pXJ-E and 0.1 μg of pXJ-myc-GST (lane 1),
asing amount of pXJ-8b-myc (lanes 5–10). Total cell lysates were subjected to
proteins (top panel). Equal amounts of cells were used in each lane as verified by
1 μg of pXJ-S and 1 μg of either pXJ-8b-myc or empty vector (lanes 1 and 2).
of 8b-myc (top panel) and S (lower panel). Equal amounts of cells were used in
ents were performed with 1 μg of pXJ-M-HA (lanes 3 and 4), 0.25 μg of pXJ-N
). (C) Vero E6 or 293T cells were co-transfected with 2 μg of pXJ-E and 1 μg of
e subjected to Western blot analysis to determine the expression of E (top panel)
the level of endogenous actin (bottom panel). (D) Indirect immunofluorescence
Vero E6 cells co-transfected with pXJ-8b and pXJ-E. The expression of 8b is
y rhodamine staining (middle panel). The merged images showed that the 8b and
Fig. 5. Effects of 8b protein on the transcription of the E gene determined by
Northern blot analysis. Equal amount of total RNA (15 μg) isolated from 293T
cells transfected with pXJ-E (lane 1), pXJ-8b-myc and pXJ-E (lane 2) cDNA
constructs or untransfected 293T (lane 3) was separated on a denaturing agarose
gel and transferred to nylon membrane. The amounts of E mRNA present were
determined by hybridization with an E gene-specific probe (top panel). In order
to verify that equal amounts of total RNAwere loaded in each lane of the agarose
gel before transfer, the amounts of 18S and 28S ribosomal RNAwere visualized
under UV light (bottom panel).
Fig. 6. Interaction between E and 8b in SARS-CoV-infected cells determined by
co-immunoprecipitation experiment. Lysates from mock-infected or SARS-
CoV-infected cells were immunoprecipitated using rabbit anti-8b polyclonal
antibody (lanes 4 and 6) or an irrelevant antibody (rabbit anti-HA polyclonal
antibody, lanes 3 and 5) and protein A-agarose beads. Western blot analyses
were then performed to determine the amount of E (upper panel) or 8b (lower
panel) present in the lysates before immunoprecipitation (lanes 1 and 2) and the
immunocomplexes on the protein A-agarose beads (lanes 3–6).
137C.-T. Keng et al. / Virology 354 (2006) 132–142detected in untransfected cells (Fig. 5, lane 3), showing that
the hybridization probe is highly specific for mRNA of E.
The experiment was repeated three times and a representative
set of data was presented.
The 8b protein can bind E protein in SARS-CoV-infected cells
Co-immunoprecipitation experiment was also performed to
determine the interaction between 8b and E in SARS-CoV-
infected cells. Lysates from mock-infected or SARS-CoV-
infected cells were immunoprecipitated using rabbit anti-8b
polyclonal antibody (Fig. 6, lanes 4 and 6) or an irrelevant
antibody (rabbit anti-HA polyclonal antibody, lanes 3 and 5).
The results showed that the E protein present in the lysates from
SARS-CoV-infected cells could bind specifically to the 8b
protein (lane 6). No unspecific binding was observed with the
irrelevant antibody (lane 5).Expressions of 8b and E are mutually exclusive in
SARS-CoV-infected cells
Indirect immunofluorescence experiments were further
performed to determine the localization of E and 8b in SARS-
CoV-infected cells. Strikingly, cells that were expressing high
levels of 8b did not have detectable levels of E (Fig. 7). Two
representative sets of data were presented and cells expressing
high levels of 8b were marked with white asterisks. Hence, it
appears that 8b can down-regulate the expression of E during
SARS-CoV infection.
Discussion
When a virus is first introduced into the human population from
an animal source, it has to undergo evolution in order to optimize
the entry, replication and budding processes as well as to evade
immune responses. Thus, genetic and epidemiological studies can
yield valuable insights on how viruses cross the species barrier and
evolve to cause disease in humans (Webby et al., 2004). Indeed,
such studies conducted on the SARS-CoV have revealed that this
virus has crossed the animal–human barrier recently (Donnelly et
al., 2004; Guan et al., 2003; Lau et al., 2005; Song et al., 2005).
Interestingly, the animal strains of SARS-CoV, isolated from a
raccoon dog and palm civets in markets/restaurants and from wild
bats, contain an extra 29-nt in the ORF8 region (Guan et al., 2003;
Lau et al., 2005; Song et al., 2005). This 29-nt sequence is not found
in all the human strains that were isolated in themiddle phase of the
epidemic but is present in most of the human isolates from the
earliest outbreaks in Guangdong, China, 2002 (The Chinese SARS
Molecular Epidemiology Consortium, 2004). Indeed, human
Fig. 7. Expressions of E and 8b in SARS-CoV-infected cells determined by
indirect immunofluorescence experiments. The expression of 8b was repre-
sented by FITC staining (top row), whereas the expression of E was represented
by Rhodamine staining (middle row). The merged images showed that the
expression of 8b and E were mutually exclusive (bottom row). Two
representative sets of data were presented and cells expressing high levels of
8b were marked with white asterisks.
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the animal–human barrier as these isolates share the closest
phylogenetic relationship with the animal isolates.
After the WHO's declaration of the end of the SARS
epidemic, there were four confirmed SARS patients in
Guangzhou, China, in late 2003 to early 2004 (Liang et al.,
2004; Song et al., 2005). These patients did not have any
contact history with previously documented SARS cases.
Sequence analysis of viruses isolated from these patients
showed that they were not derived from the preceding epidemic
in 2003 but rather suggested that these cases represented new
zoonotic transmissions (Song et al., 2005; The Chinese SARS
Molecular Epidemiology Consortium, 2004). Like the animal
isolates, these viruses also contained the additional 29-nt in the
ORF8 region.
These findings clearly indicate that the extra 29-nt sequence
in ORF8 is not necessary for the animal–human transmission.
Analysis of the variation in the sequences of S protein showed
that the SARS-CoV has rapidly evolved during the SARS
epidemic and that the virus was undergoing adaptation in the
human host (Song et al., 2005; The Chinese SARS Molecular
Epidemiology Consortium, 2004). Although it is clear that the S
gene was undergoing positive selection (Holmes, 2005),
whether the genetic variation in the ORF8 region is a result of
viral adaptation or genomic instability remains to be deter-mined. As a consequence of the additional 29-nt in the ORF8
region, the 8a and 8b protein in the human SARS-CoV,
circulating during the middle phase of the epidemic, are joined
together to form a single protein, 8ab, in the animal SARS-CoV
or human SARS-CoV from the early and late phases (Fig. 1B).
In this study, we detected the expression of 8a and 8b in Vero
E6 cells infected by a human SARS-CoV isolated from the
middle phase (SIN2774; GenBank accession number
AY283798) and showed that the cellular localizations of 8a
and 8b are distinct from 8ab (Fig. 2). We used co-immu-
noprecipitation of overexpressed proteins in mammalian cells to
determine the abilities of these proteins to interact with different
SARS-CoV proteins and showed that the binding profiles of 8a,
8b and 8ab are different (Fig. 3). Although these viral–viral
protein interactions need to be verified in infected cells, these
observations implied that there are conformational differences
between these protein when they are expressed as separate
proteins (8a and 8b) and when they are expressed as a single
fused protein (8ab).
It has been demonstrated that the palm civets are equally
susceptible to the human SARS-CoV isolate BJ01 from the
middle phase (with the 29-nt deletion) and the isolate GZ01
from the early phase (Wu et al., 2005). Using reverse genetic
methods, Yount and co-workers (2005) also reported similar
findings in the mouse model. These results suggested that the
8a, 8b and 8ab proteins are not essential for viral replication or
pathogenesis in the mouse and palm civet models. However, we
found that the expression of 8b can down-regulate the
expression of E in a dose-dependent manner (Fig. 4A) and the
expressions of 8b and E in SARS-CoV-infected cells were
mutually exclusive (Fig. 7). Interestingly, the expression of E
was not affected by either 8a or 8ab (Fig. 4A). In addition,
Northern blot analysis showed that the mRNA level of E was
not decreased in the presence of the 8b protein, suggesting that
the effect of 8b on the expression of the E protein is likely to be
post-translational (Fig. 5).
Although the co-expression of SARS-CoV E and M is
sufficient for the assembly of viral-like particles in the
baculovirus system (Ho et al., 2004; Mortola and Roy, 2004),
it was demonstrated by reverse genetic techniques that the E
protein is not essential for the replication of SARS-CoV in Vero
E6 cells (personal communication from Marta L. DeDiego and
Luis Enjuanes, Centro Nacional de Biotecnologia, Madrid,
Spain). However, the role of the E protein in SARS-CoV
replication in its natural host remains unclear. Interestingly, the
E protein is essential for the replication of the porcine
transmissible gastroenteritis virus (TGEV) (Ortego et al.,
2002) but not for the mouse hepatitis virus (MHV) (Kuo and
Masters, 2003). However, for the latter, the deletion of the E
gene reduces virus replication significantly. In addition, it was
reported that overexpression of SARS-CoV E can induce
apoptosis in T cells (Yang et al., 2005); thus, the down-
regulation of E may also have an effect on viral pathogenesis.
An interesting question that arises from our observations
concerns the regulation of 8b expression during SARS-CoV
infection. 8a and 8b are encoded by the bicistronic subgenomic
RNA 8 produced in SARS-CoV-infected cells (Marra et al.,
139C.-T. Keng et al. / Virology 354 (2006) 132–1422003; Snijder et al., 2003). Because its translation initiation
codon is not the first AUG in the subgenomic RNA, the 8b
protein is likely to be expressed via an internal ribosomal entry
mechanism or by a leaky ribosomal scanning mode of
translation, as have been described for viral proteins encoded
by other bicistronic or tricistronic coronaviral mRNAs (Liu and
Inglis, 1992; Senanayake and Brian, 1997; Thiel and Siddell,
1994). However, in order for 8b to be expressed via such
mechanisms, activation of certain host translational machineries
may be necessary (Komar and Hatzoglou, 2005; Stoneley and
Willis, 2004). Indeed, we observed that 8b was only expressed in
a fraction of the SARS-CoV-infected cells (Fig. 7). This means
that the effect of 8b on viral replication or pathogenesis is likely
to be only modulative as viral replication in those cells that did
not express high levels of 8b will be normal. However, this
modulating mechanism is not functional in the animal SARS-
CoV because 8ab does not appear to have any effect on the
expression of E. In future studies, it will be crucial to determine
the underlying mechanism regulating the expression of 8b and
its temporal expression during the viral replication cycle.
Materials and methods
Materials
All reagents used in this study were purchased from Sigma
(St. Louis, MO, USA) unless otherwise stated.
Construction of ORF8-encoded proteins
For the construction of pXJ-8a, pXJ-8a-myc, pXJ-8b and
pXJ-8b-myc, the ORF 8a and 8b were amplified by PCR using
cDNA prepared from SARS-CoV-infected cells as templates as
previously described (Tan et al., 2004a, 2004b). This strain of
virus was isolated from a Singapore patient (SIN2774;
GenBank accession number AY283798) and contained the
29-nt deletion in the ORF8 region. In order to construct aTable 2
Primers used in this study
Primer Sequence a
8a-F1 5′-CGGGATCCGCCACCATGAAACTTCTC-3′
8a-F2 b 5′-CGGGATCCACCATGGGAATGAAACTTCTC-3′
8a-F3 5′-CGGGATCCACCATGGGAATATGCACTGT-3′
8a-R1 5′-CCGCTCGAGCTAGTGTTGTACC-3′
8a-R2 5′-CCGCTCGAGTTGTGTTGTACC-3′
8b-F1 5′-CGGGATCCGCCACCATGTGCTTGAAG-3′
8b-F2b 5′-CGGGATCCACCATGGGAATGTGCTTGAAG-3′
8b-F3 5′-CGGGATCCACCATGGGAGTTTTACCTTT-3′
8b-R1 5′-CCGCTCGAGTTAATTTGTTCGT-3′
8b-R2 5′-CCGCTCGAGCCATTTGTTCGTTTATT-3′
8ab-1 5′-GTTGGTACCCAGTAGGACAAGGATCTTC-3′
8ab-2 5′-GGTTACCAACCTGAATGGAATATAAGG-3′
8ab-3 5′-TCCATTCAGGTTGGTACCCAG-3′
8ab-4 5′-AATGGAATATAAGGTACAACAC-3′
8ab-5 5′-CCTTATATTCCATTCAGG-3′
a Restriction sites introduced into primers are shown in bold face.
b Six additional base pairs (ATGGGA), which encodes for two additional amino a
8ab-myc to give a Kozak consensus ribosome binding site for more efficient translaplasmid for expressing the 8ab protein found in animal SARS-
CoVs, we used the cDNA template described above and
sequential PCR to insert the 29-nt. Primers were designed based
on the early phase human SARS-CoV isolate, GZ02, which has
the 29-nt insertion in ORF8 (GenBank accession number
AY390556). All sequences were confirmed by sequencing
performed by the core facilities at the Institute of Molecular and
Cell Biology, Singapore. All primers used in this study were
purchased from Research Biolabs, Singapore, and are listed in
Table 2.
The PCR amplicons containing ORF8a, ORF8b and
ORF8ab were cloned into the mammalian expression vector
pXJ3′HA as previously described (Tan et al., 2004a, 2004b). In
order to create a C terminus myc-tag, PCR methods were used
to insert a myc-tag (AEEQKLISEEDLLRKH) into the 3′ of the
ORFs. These proteins were tagged at their C termini to avoid
interference with their post-translational processing as both 8a
and 8ab are predicted to contain one signal peptide at their N
termini (http://www.cbs.dtu.dk/services/SignalP). The C-term-
inal HA tag present in the pXJ3′HAvector is not expressed as a
stop codon was added before the HA tag coding sequences.
Production of glutathione transferase (GST)-fusion proteins
The cDNA encoding 8a (16–39aa) and 8b (27–84aa) were
obtained by PCR methods (see Table 2 for primer sequences)
and were cloned into pGEX-4T1 vector (Amersham Bio-
sciences, Uppsala, Sweden) and transformed into E. coli BL21
(DE3) cells (Stratagene, La Jolla, CA). Expression and
purification of the GST-8aΔN15 were performed as previously
described (Tan et al., 2004a), and for long-term storage at
−20 °C, 10% glycerol was added to the purified proteins to
prevent aggregation. As for GST-8bΔN26, 2 mM DTT and
1.5% sarkosyl were included in the lysis buffer and after
sonication, Triton X-100 was added to a final concentration of
2% before the protein was purified using GSH-sepharose
beads. The purified proteins were used to immunize BALB/cSense Application
+ pXJ-8a and pXJ-8ab
+ pXJ-8a-myc and pXJ-8ab-myc
+ pGex4T1-8aΔN15
− pXJ-8a and pGex4T1-8aΔN15
− pXJ-8a-myc
+ pXJ-8b
+ pXJ-8b-myc
+ pGex4T1-8bΔN26
− pXJ-8b and pXJ-8ab and pGex4T1-8bΔN26
− pXJ-8b-myc and pXJ-8ab-myc
− Construction of 8ab
+ Construction of 8ab
− Construction of 8ab
+ Construction of 8ab
− Construction of 8ab
cids (methionine and glycine), were added to the 5′ end of 8a-myc, 8b-myc and
tion initiation.
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This was performed by trained personnel at the Biological
Resource Centre, Agency for Science, Technology and
Research (A*STAR), Singapore. GST-8bΔN26 was also used
to raise rabbit polyclonal antibodies as previously described
(Keng et al., 2005).
Transient transfections and Western blot analysis
293T and Vero E6 cells were propagated as previously
described (Tan et al., 2004b) and transient transfections were
performed using Lipofectamine reagent (Invitrogen, Carlsbad,
CA), according to manufacturer's protocol. Western blot
analysis were performed as previously described (Tan et al.,
2004b) and some of the primary antibodies (anti-HA mono-
clonal (Roche Molecular Biochemicals, Indianapolis, Ind.) and
anti-myc monoclonal (Santa Cruz Biotechnology, Santa Cruz,
CA)) were purchased. The mouse anti-N, anti-E, anti-3a and
anti-7a polyclonal antibodies have been described previously
(Fielding et al., 2004; Guan et al., 2004; Tan et al., 2004b),
whereas the mouse anti-8a and anti-8b polyclonal antibodies
were produced for this study as described above. Anti-S
monoclonal antibody (clone 1G10) has been described
previously (Lip et al., 2006).
Immunofluorescence and co-immunoprecipitation experiments
Transiently transfected and SARS-CoV-infected Vero E6
cells were subjected to indirect immunofluorescence experi-
ments as previously described (Tan et al., 2004b). For each co-
immunoprecipitation experiment, one 6-cm dish of 293T cells
was co-transfected with pXJ-myc-GST, pXJ-8a-myc, pXJ-8b-
myc or pXJ-8ab-myc and the DNA construct for expressing one
of the other viral proteins (S, E, M-HA, N, 3a or 7a). These
DNA constructs have been previously described (Fielding et al.,
2004; Tan et al., 2004a, 2004b). Untagged forms of S, N, E, 3a
and 7a were used whereas a C-terminally HA-tagged M (M-
HA) was used because no suitable anti-M antibody was
available.
Due to the differences in the binding affinity of the different
antibodies used for detection (i.e., anti-S, anti-E, anti-HA, anti-
N, anti-3a and anti-7a), the amount of DNA plasmids required
for each co-immunoprecipitation experiments was determined
experimentally to ensure that good signals were obtained in
Western blot analysis. In all cases (except for Fig. 3B, lane 3),
the amount of pXJ-myc-GST, pXJ-8a-myc, pXJ-8b-myc and
pXJ-8ab-myc used were 0.1 μg, 1 μg, 2 μg and 1 μg,
respectively. The amount of pXJ-S (1 μg), pXJ-E (1 μg, except
for Fig. 3B, lane 3), pXJ-M-HA (1 μg), pXJ-N (0.25 μg), pXJ-
3a (0.4 μg) and pXJ-7a (0.4 μg) used are given in parentheses.
Due to the effects of 8b on the expression of E, the amount of
DNA plasmids used for Fig. 3B, lane 3, were 0.5 μg of pXJ-8b-
myc and 2 μg of pXJ-E.
The cells were harvested at 16 h post-transfection and
washed with PBS. Then, the cells were resuspended in 150 μl of
IP buffer (50 mM Tris pH 8, 150 mM NaCl, 0.5% NP40, 0.5%
deoxycholic acid, 0.005% SDS) supplemented with 0.5% TritonX-114 and subjected to sonication for 45 min using an
ultrasonic processor (Sonics, Newtown, CT, USA), followed
by freeze–thawing for six times. 100 μl of the lysates were
diluted with 100 μl of IP buffer and 5 μl of rabbit anti-myc
polyclonal antibody (Santa Cruz Biotechnology) were added
and the mixture was subjected to end-over-end mixing at 4 °C
for 2 h. Protein A-agarose beads (Roche) were then added and
the mixing continued for at least 4 h at 4 °C. Beads were washed
three times with cold IP buffer and then 20 μl of Laemmli's SDS
buffer were added and the samples boiled at 100 °C for 5 min to
release the immunocomplexes. As the M and 3a proteins tend to
form large aggregates when boiled, samples containing M-HA
or 3a were heated at 50 °C for 30 min, followed by 100 °C for
1 min. Samples were separated on SDS–PAGE and subjected to
Western blot analysis. In some cases, tricine gels (BIORAD,
Hercules, CA) were used instead for better resolution of low
molecular weight proteins.
Co-immunoprecipitation experiments with SARS-CoV-
infected cells were performed in a similar manner. Lysates
obtained from SARS-CoV-infected Vero E6 cells were
subjected to immunoprecipitation with either rabbit anti-8b
polyclonal antibody or an unrelated antibody (anti-HA poly-
clonal, Y11, Santa Cruz Biotechnology) and protein-A agarose
beads. Western blot analyses were then performed to detect the
amount of E (using mouse anti-E polyclonal antibody) and 8b
(using rabbit anti-8b polyclonal antibody) present in the
immunocomplexes on the protein-A agarose beads.
Northern blot analysis
Total RNA from 293T cells transfected as described above
was extracted using the RNeasy mini kit (Qiagen, Valencia,
CA, USA) by following the protocol supplied by the
manufacturer. The final RNA pellet was resuspended in
diethyl pyrocarbonate-treated H2O and quantified by measur-
ing absorbance at 260 nm. 15 μg of total RNA was separated
on 1.2% denaturing agarose-formaldehyde gel (containing
ethidium bromide), transferred overnight in 1× saline-sodium
citrate (SSC) buffer to nylon membranes Hybond N+
(Amersham Biosciences). The blot was dried at room
temperature for 30 min and baked at 80 °C for 30 min. The
blot was then pre-hybridized with salmon testes DNA (Sigma)
in hybridization buffer containing 6× SSC, 2× Denhardt's
Reagent and 0.1% sodium dodecyl sulfate (SDS) for 2 h. The
E gene cDNA fragment was cloned into the TA cloning vector
pCRII-TOPO (Invitrogen) and linearized with Hind III
restriction enzyme. Probes were generated from the linearized
plasmid using T7 polymerase from the DIG RNA labeling kit
(Roche). Hybridization was performed overnight at 68 °C with
the DIG-labeled probe in the hybridization buffer. After
hybridization, the blot was washed once for 20 min in 1×
SSC buffer with 0.1% SDS followed by 3 washes, each
30 min, in 0.2× SSC with 0.1% SDS. All washes were
performed at room temperature. The blot was then probed with
alkaline phosphatase-conjugated anti-digoxigenin antibody and
developed using chemiluminescence substrate CSPD (DIG
luminescent detection kit, Roche). This was performed
141C.-T. Keng et al. / Virology 354 (2006) 132–142according to the manufacturer's protocol and the results were
obtained by autoradiography. RNA ladders from Fermentas
Life Sciences (Ontario, Canada) were used for size determina-
tion of mRNA.
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